U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343453) titled 'A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors' on Jan. 06.
Brief Summary: This is a single-arm, phase II study to evaluate the efficacy and safety of Sacituzumab Tirumotecan, a TROP2-directed antibody-drug conjugate, in patients with advanced thymic epithelial tumors who have received second-line or later therapy.
Study Start Date: Dec. 22, 2025
Study Type: INTERVENTIONAL
Condition:
Thymic Epithelial Tumors
Advanced Stage
Second-line Therapy
Intervention:
DRUG: Sacituzumab tirumotecan
Sacituzumab Tirumo...